Skip main navigation

Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?

Originally publishedhttps://doi.org/10.1161/CIRCHEARTFAILURE.112.000381Circulation: Heart Failure. 2013;6:869–876

    Introduction

    Current therapies for acute heart failure (AHF) mainly focus on the restoration of hemodynamic stability and fluid balance.1 Recent decades of therapeutic investigations in AHF have generally failed to improve patient outcomes.2,3 These data are in contrast to the ongoing improvements in survival in patients with chronic HF.3 This disconnect may be in part because of the better understanding of the pathophysiology of chronic HF, allowing for the development of targeted therapeutic strategies. Conversely, the specific mechanisms leading to the development of AHF and the associated adverse outcomes remain unclear.3 Hence, there is an ongoing need to identify and test novel therapeutic targets in AHF.

    HF is associated with activation of the renin–angiotensin–aldosterone system, sympathetic nervous system, and mechanisms of inflammation and oxidative stress.4 Each of these pathways may directly influence the chronic progression of cardiac dysfunction and acute decompensation. In addition, these mediators may contribute indirectly through the activation of other pathophysiologic mechanisms, which have not been fully elucidated. One such potential mechanism is platelet activation.5,6 The activation of neurohormonal, inflammatory, and thrombotic pathways79 is known to be associated with enhanced platelet reactivity in AHF.1014 However, whether increased platelet activity is simply a marker of this systemic imbalance or an actual contributor to acute decompensation is incompletely understood. Several pathophysiologic mechanisms that may explain a possible detrimental role of platelet activation on the myocardium have been described.6,15,16 Myocardial injury, as manifest clinically by elevations of cardiac troponin,17,18 may represent a connection between platelet activation and poor prognosis. If a causal role for platelet activation can be confirmed in the AHF setting, specific antiplatelet therapies might improve prognosis in this high-risk population. In this article, we summarize the data supporting the hypothesis of a beneficial effect of antiplatelet therapy in AHF. We focus on the pathophysiological mechanisms of platelet activation possibly related to HF, present the relevant studies investigating antiplatelet therapy in HF, and highlight the unanswered questions and need for future study.

    Evidence of Platelet Activation in HF

    Platelet reactivity can be assessed by a variety of methods, including evaluation of aggregation capacity and levels of circulating factors expressed at the time of platelet activation.19 The optimal method to quantify the physiological and pathological function of platelets has not been established.20 In HF patients, several markers have been investigated. Mean platelet volume is routinely measured by automated cell counters and is associated with thrombotic potential.10,19 Other markers include molecules that mediate platelet activation and interaction with other cells. On platelet activation, these molecules may be exposed on the platelet surface (eg, platelet/endothelial cell adhesion molecule-1, osteonectin), secreted in a soluble form (eg, β-thromboglobulin) or both (eg, P-selectin, CD-40 ligand).19 Soluble markers are more easily measured than platelet-bound markers, but the association between these markers is unclear. Routine use of these markers is not well established because of several limitations. First, most markers lack specificity as they are expressed not only by platelets but also by leukocytes or endothelial cells.20 Moreover, specimens are prone to collection and processing artifacts. Finally, the lack of standardized methods for analysis may limit reproducibility.21

    These limitations may explain, in part, why investigations exploring platelet activation in HF have yielded conflicting results. Studies investigating platelet markers in HF have been relatively small in size and heterogeneous with respect to design, marker assessment, and measurement technique1014,21–28 (Table 1). In these studies, a certain degree of baseline platelet activation seems to be present in patients with HF. Subjects with HF exhibit greater variability in these biomarkers compared with consistently low levels in healthy controls.13,22 Another consistent finding is that markers of platelet activation are elevated regardless of HF pathogenesis and previous treatment with aspirin.23,25,27 Of note, patients with HF have similar levels of platelet markers compared with patients with coronary disease without HF.21,24,26 The severity of HF and comorbid disease may be associated with the degree of platelet activation in HF.24,26

    Table 1. Representative Studies Investigating Markers of Platelet Activation in Heart Failure

    MarkerStudyGroup ComparisonResultsAssociation With PrognosisIndependent From PathogenesisAssociation With SeverityEffect of Aspirin
    Mean platelet volumeChung et al11Acute vs chronic HF and healthy controlsChronic HF>healthy controls; no significant difference for acute HFn/an/an/an/a
    Kandis et al10Acute vs chronic HFAcute>chronic HFYesn/an/an/a
    Chung et al21Chronic HF vs disease and healthy controlsDisease>healthy controls, chronic HF=disease controlsNoYesNon/a
    P-selectin
     P- and s-formO’Connor et al13Acute HF vs healthy controlsAcute HF>healthy controlsn/an/aNoNo
    Chung et al24Chronic HF vs disease and healthy controlsChronic HF>healthy controls; no difference with disease controlsNoYesNYHA (p-form)n/a
    Chung et al11Acute vs chronic HF and healthy controlsAcute HF>chronic HF>healthy controls; decrease at follow-up for acute HF (p-form); and no differences between groups for s-formn/an/an/an/a
     P-formGurbel et al23Chronic HF vs healthy controlsChronic HF>healthy controlsNoYesNoNo
    Stumpf et al27Chronic or acute HF vs healthy controls, ischemic HF vs disease controlsHF>healthy controls; ischemic HF>disease controlsn/aYesNYHANo
    Milo et al12Acute vs chronic HFAcute>chronic HF; decrease at follow-up for acute HFNoYesn/an/a
     S-formYin et al28Chronic HF vs healthy controlsChronic HF>healthy controlsYesn/aNYHA, EFn/a
    CD-40 ligand
     P- and s-formStumpf et al27Chronic or acute HF vs healthy controls, ischemic HF vs disease controlsHF>healthy controls (p-form); no differences for s-formn/aYesNYHA (p-form)No
    Chung et al21Chronic HF vs disease and healthy controlsChronic HF>disease controls (total); no differences for p- and s- formsNoBorderlineP-form in LVEF>35%n/a
     S-formUeland et al14Acute HF following MI vs chronic HF and healthy controlsAcute HF>healthy controls; chronic HF>healthy controlsTrend; n/an/a; YesNYHA; NYHA, EFn/a
     P-formChung et al11Acute HF vs chronic HF and healthy controlsNo differences between groups; decrease at follow-up for acute HFn/an/an/an/a
    PECAM–1Serebruany et al25Chronic HF vs healthy controlsChronic HF>healthy controlsn/aYesn/aNo
    OsteonectinSerebruany et al25Chronic HF vs healthy controlsChronic HF>healthy controlsn/aYesn/aNo
    ThromboglobulinJafri et al26Chronic HF vs disease and healthy controlsChronic HF>healthy controls; chronic HF=disease controlsn/aYesEF, NE levelsn/a

    EF indicates ejection fraction; HF, heart failure; n/a, not assessed; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NE, norepinephrine; NYHA, New York Heart Association; PECAM, platelet/endothelial cell adhesion molecule; p-form, platelet-bound form; and s-form, soluble form.

    The difference between the levels of platelet activation biomarkers in acute versus chronic HF is less clear.1012 In general, markers of platelet activation are reduced with AHF therapies and further reductions occur during follow-up.11,12 These data support the hypothesis of a direct association between platelet activation and AHF decompensation. In contrast, conflicting data have been observed with regard to the association of platelet biomarkers with prognosis.7,9,21,23,24 Notably, the small size of these previous studies underscores the need for ongoing exploration of the biology of platelet activation in HF.

    Pathophysiology of Platelet Activation

    Several mechanisms that are activated in chronic HF and further enhanced during acute decompensation may promote a prothrombotic state9 and may explain, in part, the observed increased platelet reactivity.5 Endothelial damage and dysfunction along with imbalances in nitric oxide production and increased expression of adhesion molecules may lead to enhanced platelet adhesion and activation.7,29 In addition, increased levels of angiotensin II and circulating catecholamines,7,8 oxidative stress, and inflammation30,31 contribute to the increased activity of platelets and the coagulation cascade.16 Although these mechanisms can lead to platelet activation, the extent to which this activation may play a direct role in the pathophysiology of AHF remains unclear.

    One mechanism that may link platelet activation and adverse outcomes in AHF is myocardial injury. Myocardial injury, as shown by elevations in circulating cardiac troponin, occurs in the context of AHF even in the absence of overt ischemia. The reported prevalence of elevated troponin varies widely across studies, depending on the specific population, assay, and threshold used.18 Increased troponin levels on admission for AHF are associated with higher rates of in-hospital mortality, and postdischarge morbidity and mortality.17,32 The predictive value of increased troponin levels seems to be independent and additive to that of other biomarkers, such as natriuretic peptides.18 Therefore, mechanisms other than myocardial strain because of left ventricular volume overload seem to be involved in myocardial damage during AHF. However, the causes of troponin release during AHF are likely multifactorial and not completely understood.17,18

    The potential role of platelet activation as a link between HF decompensation and troponin elevation requires further investigation. Support for the association between increased troponin levels and platelet activation may be extrapolated from studies in ischemic heart disease. The degree of platelet activation has been associated with troponin levels in small studies of patients with non–ST-elevation acute coronary syndromes,33,34 as well as revascularization studies.34,35 Possible pathways through which platelet activation may contribute to the myocardial damage observed in AHF include vasoconstriction and the deposition of platelet aggregates, subsequently leading to microvascular damage and ischemia. In fact, the platelet response to agonists, such as ADP, involves not only platelet aggregation but also secretion of several vasoactive agents, such as serotonin and thromboxane A2.7 Animal models have demonstrated that these substances cause vasoconstriction and further promote platelet aggregation.15

    Role of Coagulation and Hemostasis

    Although distinct from the pathophysiology of platelet activation in AHF, the coagulation cascade is relevant to the discussion of hematologic perturbations during HF hospitalizations. AHF may increase the risk for thrombotic complications through each of the mechanisms of Virchow’s triad, including abnormalities in the vessel walls, blood flow, and blood constituents as recently reviewed.36 In contrast to the low risk for venous thromboembolism (VTE) in chronic HF patients,37 patients with severe medical illnesses, including AHF, are at high risk for VTE.38 Notably, the risk associated with HF seems to be highest in the early period after HF diagnosis with attenuation over time.39

    Despite the thrombotic risk associated with HF, multiple trials investigating the use of anticoagulation in chronic HF patients in sinus rhythm,4042 as well as extended VTE prophylaxis after hospitalization in medically ill cohorts (including those with AHF), have demonstrated marginal43 to no net clinical benefit.44,45 Thus, consensus documents have recommended against the broad use of anticoagulation in these patients and have reserved use for select patients based on the individualized risk–benefit ratio.36 In fact, the recent 2012 American College of Chest Physicians guidelines for hospitalized medical patients differ significantly from those of 2008, which recommended anticoagulant prophylaxis on the basis of HF alone, and now indicate that increased-risk and low-risk patients should be distinguished using a risk assessment tool with administration of anticoagulant restricted to those at increased risk.46 Thus, many HF patients that would have been recommended to receive anticoagulation by the 2008 guidelines no longer qualify by the most recent guidelines unless they have high risk features, such as active cancer, previous VTE, reduced mobility, and advanced age. The potential for significantly reduced mobility early during AHF hospitalization and the advanced age of the HF population represent several key characteristics that place this group at increased risk for VTE and highlight the need for further prospective study to increase the evidence base for these recommendations.

    An ongoing trial on the basis of lessons learned from these earlier studies is investigating the use of a novel oral anticoagulant, betrixaban, in the subgroup of hospitalized patients at highest risk for VTE (eg, cardiac or respiratory failure with advanced age and severe immobility; ClinicalTrials.gov identifier: NCT01583218). This study may help answer whether there is a potential role for anticoagulation in addition to (or in place of) antiplatelet therapy during AHF.

    Evidence for Efficacy of Antiplatelet Therapy

    Limited data are available with regard to the use of antiplatelet therapy in patients with HF in sinus rhythm4042,47,48 (Table 2). Therefore, whether antiplatelet therapy may be a useful strategy to improve prognosis in patients with AHF remains largely unexplored. Aspirin and clopidogrel are the most commonly investigated and used antiplatelet drugs. Aspirin’s mechanism of action involves the irreversible acetylation of the enzyme cyclooxygenase, which inhibits the production of thromboxane A2 and prostaglandin in platelets, and prostaglandin I2 in vascular cells. In platelets, cyclooxygenase inhibition leads to a reduction in aggregation, whereas in the vessels this causes a decrease in vasodilating properties.49 Concern has been raised with regard to the vascular effect of prostaglandin synthesis blockade that may be detrimental in patients with HF, by diminishing vasodilating properties of glomerular afferent arterioles, and leading to worsen kidney function and sodium retention. Evidence of an association between increased HF hospitalization and aspirin use in chronic HF patients was seen in the Warfarin–Aspirin Study in HF (WASH) and Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trials,40,41 but the contemporary Warfarin–Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial did not support this association.42 As the largest trial of antithrombotic therapy in HF patients in sinus rhythm with rigorous methodology involving a double-blind, double-dummy study design, the lack of association between aspirin and HF hospitalizations in WARCEF should reduce concerns related to potential adverse effects of antiplatelet therapy on worsening HF.

    Table 2. Intervention Trials on Antiplatelet Therapy in Patients With Heart Failure and Reduced Ejection Fraction

    Study (year)DesignPrimary End PointSizeResults
    PLUTO-CHF* (2003)48Randomized, single-blind trial on patients increased platelet reactivity, comparing clopidogrel+aspirin and aspirin aloneDecrease in markers of platelet activation50Combined treatment significantly decreased platelet reactivity compared with aspirin alone
    WASH (2004)40Randomized, open-label trial comparing no antithrombotic therapy, aspirin, and warfarinDeath, nonfatal MI, or nonfatal stroke279Underpowered because of slow enrollment. No significant difference for primary end point. All-cause and HF hospitalization higher in patients with aspirin
    HELAS (2006)47Randomized double-blind trial. Patients with ischemic HF randomized to aspirin or warfarin. Patients with idiopathic dilated cardiomyopathy randomized to either warfarin or placeboAny of nonfatal stroke, peripheral or pulmonary embolism, MI, rehospitalization, HF, or all-cause death197Underpowered study because of slow enrollment. No significant differences among groups
    WATCH (2009)41Randomized trial comparing open-label warfarin and double-blind treatment with either aspirin or clopidogrelTime to first event in a composite end point of death, nonfatal MI, or nonfatal stroke1587Underpowered because of slow enrollment. No significant differences for primary composite end point among the 3 groups. No difference in end points between aspirin and clopidogrel. Hospitalization for worsening HF more frequent in patients treated with aspirin vs warfarin. Lower risk of stroke and higher risk of hemorrhage in warfarin patients
    WARCEF (2012)42Randomized, double-blind trial comparing aspirin or warfarinTime to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or all-cause death2305Underpowered because of slow enrollment. No difference in the rate of main composite end point. The hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up. Lower risk for ischemic stroke and higher risk of hemorrhage for warfarin. No evidence of higher HF hospitalization with aspirin

    HELAS indicates Heart Failure Long-term Antithrombotic Study; HF, heart failure; MI, myocardial infarction; PLUTO-CHF, Plavix Use for Treatment of Congestive Heart Failure; WARCEF, Warfarin–Aspirin in Reduced Cardiac Ejection Fraction; WASH, Warfarin–Aspirin Study in Heart Failure; and WATCH, Warfarin and Antiplatelet Therapy in Chronic Heart Failure.

    *Study included both reduced and preserved ejection fraction.

    Another matter of concern has been a possible adverse interaction of aspirin with angiotensin-converting enzyme (ACE) inhibitors,50 which was initially supported by post hoc analyses of large ACE-inhibitor trials.51,52 The hypothesized mechanism for worse outcomes involves aspirin’s effects at the prostaglandin level with attenuation of ACE-inhibitor–mediated bradykinin benefits related to systemic arterial vasodilation and cardiac remodeling.53 However, these associations have generally been refuted by more recent studies.5456 For instance, in the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, aspirin use in combination with either an ACE inhibitor or an angiotensin receptor blocker was not associated with adverse events post discharge for AHF in patients with ischemic or nonischemic HF.56 Thus, contemporary studies derived from registry data and population-based cohorts57 have refuted earlier concerns related to a potential aspirin and ACE-inhibitor interaction that was seen in early clinical trials with strict entry criteria.

    Uncertainties on aspirin use in HF patients and the availability of alternative methods to inhibit platelet aggregation led to the investigation of clopidogrel use in HF. Clopidogrel is a thienopyridine, which can irreversibly inhibit platelet ADP-dependent activation, blocking the platelet ADP receptor P2Y12. Clopidogrel decreases the expression of platelet surface receptors58 without effects on prostaglandin inhibition. A retrospective study of 20 000 patients with incident HF investigated outcomes on the basis of antithrombotic drug regimen: warfarin alone, warfarin plus antiplatelet therapy, clopidogrel (alone or in addition to aspirin), aspirin alone, and no therapy.59 Various modeling approaches performed on this population showed the highest risk for mortality for patients with no antithrombotic therapy, and a decreasing risk for those treated with aspirin, clopidogrel, and the lowest risk for patients treated with warfarin. In another recent registry of 50 000 patients hospitalized with first-time myocardial infarction and no percutaneous coronary intervention,60 the authors compared patients by the presence or absence of HF and treatment with clopidogrel. The survival of patients without HF was comparable between patients with or without clopidogrel, whereas a significant survival benefit of clopidogrel was observed in the patients with HF (Figure 1). Another, smaller study of patients hospitalized for AHF showed lower mortality rates in patients taking clopidogrel, or aspirin plus clopidogrel versus a control group not receiving antiplatelet therapy.61 Aspirin use alone was not associated with a difference in outcome. These findings support the hypothesis that platelet activation may play a key role in the poor prognosis of HF patients and suggest a possible therapeutic benefit with clopidogrel.

    Figure 1.

    Figure 1. Survival in patients with first-time myocardial infarction (MI), subdivided according to the presence or absence of heart failure (HF) and treatment with clopidogrel. Reprinted from Bonde et al,60 with permission from Elsevier.

    The potential benefits of the more recently developed antiplatelet agents (prasugrel, ticagrelor) have not yet been tested in HF patients.

    Gaps and Future Directions

    Platelet activation is a largely unexplored potential therapeutic target for AHF. Figure 2 shows a possible framework for linking platelet activation, myocardial injury, and poor outcomes and offers potential areas that could be addressed by appropriately designed studies. A substantial challenge is the lack of a standardized, effective measurement of platelet activity. Second, further exploration is required to determine the degree of platelet activation that is present in AHF patients. The specificity of enhanced platelet activity for AHF patients as compared with stable chronic HF and other controls is unclear. The extent to which platelet activity may be related to myocardial damage and prognosis also requires further study. These issues are still unresolved mainly because of the lack of adequately powered, targeted studies. Large prospective observational studies of AHF patients, assessing the association among different platelet activity markers, natriuretic peptides, markers of myocardial damage, and prognosis could provide a significant first step in understanding the potential therapeutic benefit of antiplatelet agents in these patients. Stable chronic HF patients could serve as a control group. Such a study may also allow the identification of the most useful platelet markers, and higher risk patients’ subgroups to target in future intervention studies.

    Figure 2.

    Figure 2. A framework for the relationship between acute heart failure, platelet activation, myocardial injury, and poor outcome. NO indicates nitric oxide; RAAS, renin–angiotensin–aldosterone system; and SNS, sympathetic nervous system.

    If the association among platelet activity, myocardial damage, and poor prognosis in AHF is confirmed, subsequent studies will need to clarify the impact of antiplatelet therapy on outcomes. The observational studies to date demonstrate the need for further empirical testing given the difficulties in adjustment for bias in nonrandomized populations. Previous prospective, randomized trials of antiplatelet therapies did not investigate the AHF population or directly compare antiplatelet therapies. A randomized controlled study may answer this question by comparing different antiplatelet drugs and placebo in a cohort of AHF patients with further assessment of the association among treatment, platelet biomarkers, and prognosis.

    Conclusions

    Platelet activation may represent an unaddressed target of AHF therapy. There is evidence suggesting that platelet activation is present in the setting of AHF, which may contribute to the myocardial damage and may be related to patients’ poor outcome. Therefore, antiplatelet therapy may be beneficial if initiated in patients during an episode of AHF. However, current evidence is insufficient to support or refute the hypothesis of a direct role of platelet activation in the pathophysiology of AHF or a possible role for antiplatelet therapies. Overall, the studies performed to date have underlined the need for pursuing antiplatelet research in HF with adequately designed trials.

    Footnotes

    Correspondence to G. Michael Felker, MD, Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705. E-mail

    References

    • 1. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure.J Am Coll Cardiol. 2012; 59:2145–2153.CrossrefMedlineGoogle Scholar
    • 2. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O’Connell J, O’Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M; International AHFS Working Group. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward.Circ Heart Fail. 2010; 3:314–325.LinkGoogle Scholar
    • 3. McDonagh TA, Komajda M, Maggioni AP, Zannad F, Gheorghiade M, Metra M, Dargie HJ. Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009.Eur J Heart Fail. 2011; 13:1253–1260.CrossrefMedlineGoogle Scholar
    • 4. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Pina IL, Fiuzat M, O’Connor CM, Zannad F, Pitt B. The past, present and future of renin-angiotensin aldosterone system inhibition.Int J Cardiol2012; pii:S0167-S5273(12)01381–01382.MedlineGoogle Scholar
    • 5. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited.J Am Coll Cardiol. 1999; 33:1424–1426.MedlineGoogle Scholar
    • 6. Davis CJ, Gurbel PA, Gattis WA, Fuzaylov SY, Nair GV, O’Connor CM, Serebruany VL. Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge.Int J Cardiol. 2000; 75:15–21.CrossrefMedlineGoogle Scholar
    • 7. Michibayashi T. Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways.J Atheroscler Thromb. 2005; 12:154–162.CrossrefMedlineGoogle Scholar
    • 8. Badimon L, Martínez-González J, Royo T, Lassila R, Badimon JJ. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall–studies in a porcine model.Thromb Haemost. 1999; 82:1736–1742.CrossrefMedlineGoogle Scholar
    • 9. Bettari L, Fiuzat M, Becker R, Felker GM, Metra M, O’Connor CM. Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions.Circ Heart Fail. 2011; 4:361–368.LinkGoogle Scholar
    • 10. Kandis H, Ozhan H, Ordu S, Erden I, Caglar O, Basar C, Yalcin S, Alemdar R, Aydin M. The prognostic value of mean platelet volume in decompensated heart failure.Emerg Med J. 2011; 28:575–578.CrossrefMedlineGoogle Scholar
    • 11. Chung I, Choudhury A, Lip GY. Platelet activation in acute, decompensated congestive heart failure.Thromb Res. 2007; 120:709–713.CrossrefMedlineGoogle Scholar
    • 12. Milo O, Cotter G, Kaluski E, Brill A, Blatt A, Krakover R, Vered Z, Hershkoviz R. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes.Am J Cardiol. 2003; 92:222–226.CrossrefMedlineGoogle Scholar
    • 13. O’Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure.Am J Cardiol. 1999; 83:1345–1349.CrossrefMedlineGoogle Scholar
    • 14. Ueland T, Aukrust P, Yndestad A, Otterdal K, Frøland SS, Dickstein K, Kjekshus J, Gullestad L, Damås JK. Soluble CD40 ligand in acute and chronic heart failure.Eur Heart J. 2005; 26:1101–1107.CrossrefMedlineGoogle Scholar
    • 15. Golino P, Ashton JH, Buja LM, Rosolowsky M, Taylor AL, McNatt J, Campbell WB, Willerson JT. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators.Circulation. 1989; 79:154–166.LinkGoogle Scholar
    • 16. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy.J Am Coll Cardiol. 1995; 25:1634–1640.CrossrefMedlineGoogle Scholar
    • 17. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications.J Am Coll Cardiol. 2010; 56:1071–1078.CrossrefMedlineGoogle Scholar
    • 18. Januzzi JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section.Eur Heart J. 2012; 33:2265–2271.CrossrefMedlineGoogle Scholar
    • 19. Sharma G, Berger JS. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.J Thromb Thrombolysis. 2011; 32:201–208.CrossrefMedlineGoogle Scholar
    • 20. Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: does it exist?Am J Hematol. 2002; 70:139–144.CrossrefMedlineGoogle Scholar
    • 21. Chung I, Choudhury A, Patel J, Lip GY. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity.J Intern Med. 2008; 263:313–321.CrossrefMedlineGoogle Scholar
    • 22. Serebruany VL, McKenzie ME, Meister AF, Fuzaylov SY, Gurbel PA, Atar D, Gattis WA, O’Connor CM. Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure.Pathophysiol Haemost Thromb. 2002; 32:8–15.MedlineGoogle Scholar
    • 23. Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O’Connor CM. Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?Am Heart J. 2002; 143:1068–1075.CrossrefMedlineGoogle Scholar
    • 24. Chung I, Choudhury A, Patel J, Lip GY. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure.Ann Med. 2009; 41:45–51.CrossrefMedlineGoogle Scholar
    • 25. Serebruany VL, Murugesan SR, Pothula A, Atar D, Lowry DR, O’Connor CM, Gurbel PA. Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy.Eur J Heart Fail. 1999; 1:243–249.CrossrefMedlineGoogle Scholar
    • 26. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure.Eur Heart J. 1993; 14:205–212.CrossrefMedlineGoogle Scholar
    • 27. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure.Eur J Heart Fail. 2003; 5:629–637.CrossrefMedlineGoogle Scholar
    • 28. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Lin SJ, Young MS. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure.Eur J Heart Fail. 2003; 5:507–516.CrossrefMedlineGoogle Scholar
    • 29. Habib F, Dutka D, Crossman D, Oakley CM, Cleland JG. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism?Lancet. 1994; 344:371–373.CrossrefMedlineGoogle Scholar
    • 30. Paulus WJ. Cytokines and heart failure.Heart Fail Monit. 2000; 1:50–56.MedlineGoogle Scholar
    • 31. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N Engl J Med. 1990; 323:236–241.CrossrefMedlineGoogle Scholar
    • 32. Peacock WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure.N Engl J Med. 2008; 358:2117–2126.CrossrefMedlineGoogle Scholar
    • 33. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes.Clin Cardiol. 2007; 30:26–31.CrossrefMedlineGoogle Scholar
    • 34. Ray MJ, Walters DL, Bett JN, Cameron J, Wood P, Aroney CN. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.Int J Cardiol. 2005; 101:249–255.CrossrefMedlineGoogle Scholar
    • 35. Rinder CS, Mathew JP, Rinder HM, Greg Howe J, Fontes M, Crouch J, Pfau S, Patel P, Smith BR; Multicenter Study of Perioperative Ischemia Research Group. Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass.Anesthesiology. 2002; 97:1118–1122.CrossrefMedlineGoogle Scholar
    • 36. Lip GY, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, Marin F, Lane DA; ESC Task Force. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.Eur J Heart Fail. 2012; 14:681–695.CrossrefMedlineGoogle Scholar
    • 37. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.Circulation. 1993; 87(suppl 6):VI94–V101.MedlineGoogle Scholar
    • 38. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.Arch Intern Med. 2002; 162:1245–1248.CrossrefMedlineGoogle Scholar
    • 39. Alberts VP, Bos MJ, Koudstaal P, Hofman A, Witteman JC, Stricker B, Breteler M. Heart failure and the risk of stroke: the Rotterdam Study.Eur J Epidemiol. 2010; 25:807–812.CrossrefMedlineGoogle Scholar
    • 40. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.Am Heart J. 2004; 148:157–164.CrossrefMedlineGoogle Scholar
    • 41. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O’Connor CM, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.Circulation. 2009; 119:1616–1624.LinkGoogle Scholar
    • 42. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm.N Engl J Med. 2012; 366:1859–1869.CrossrefMedlineGoogle Scholar
    • 43. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.Ann Intern Med. 2010; 153:8–18.CrossrefMedlineGoogle Scholar
    • 44. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.N Engl J Med. 2013; 368:513–523.CrossrefMedlineGoogle Scholar
    • 45. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.N Engl J Med. 2011; 365:2167–2177.CrossrefMedlineGoogle Scholar
    • 46. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012; 141(suppl 2):e195S–e226S.CrossrefMedlineGoogle Scholar
    • 47. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.Eur J Heart Fail. 2006; 8:428–432.CrossrefMedlineGoogle Scholar
    • 48. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O’connor CM. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.Am Heart J. 2003; 146:713–720.CrossrefMedlineGoogle Scholar
    • 49. Vane JR, Botting RM. The mechanism of action of aspirin.Thromb Res. 2003; 110:255–258.CrossrefMedlineGoogle Scholar
    • 50. Spaulding C, Charbonnier B, Cohen-Solal A, Juillière Y, Kromer EP, Benhamda K, Cador R, Weber S. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial.Circulation. 1998; 98:757–765.LinkGoogle Scholar
    • 51. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II).Am J Cardiol. 1997; 79:115–119.CrossrefMedlineGoogle Scholar
    • 52. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.J Am Coll Cardiol. 1998; 31:419–425.CrossrefMedlineGoogle Scholar
    • 53. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.Am J Med. 2000; 109:371–377.CrossrefMedlineGoogle Scholar
    • 54. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R; ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.Lancet. 2002; 360:1037–1043.CrossrefMedlineGoogle Scholar
    • 55. McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.Circulation. 2006; 113:2572–2578.LinkGoogle Scholar
    • 56. Levy PD, Nandyal D, Welch RD, Sun JL, Pieper K, Ghali JK, Fonarow GC, Gheorghiade M, Gheorgiade M, O’Connor CM. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).Am Heart J. 2010; 159:222–230, e2.CrossrefMedlineGoogle Scholar
    • 57. Masoudi FA, Wolfe P, Havranek EP, Rathore SS, Foody JM, Krumholz HM. Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes.J Am Coll Cardiol. 2005; 46:955–962.CrossrefMedlineGoogle Scholar
    • 58. Coukell AJ, Markham A. Clopidogrel.Drugs. 1997; 54:745–50; discussion 751.CrossrefMedlineGoogle Scholar
    • 59. Yuan Z, Weinstein R, Zhang J, Cheng M, Griffin G, Zolynas R, Plotnikov AN, Lee MS, Oppenheimer L, Burton P. Antithrombotic therapies in patients with heart failure: hypothesis formulation from a research database.Pharmacoepidemiol Drug Saf. 2010; 19:911–920.CrossrefMedlineGoogle Scholar
    • 60. Bonde L, Sorensen R, Fosbøl EL, Abildstrøm SZ, Hansen PR, Kober L, Schramm TK, Bretler DM, Weeke P, Olesen J, Torp-Pedersen C, Gislason GH. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study.J Am Coll Cardiol. 2010; 55:1300–1307.CrossrefMedlineGoogle Scholar
    • 61. Kozdağ G, Yaymaci M, Ertaş G, Celikyurt U, Sahin T, Kiliç T, Ural D. Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure.Heart Vessels. 2012; 27:568–575.CrossrefMedlineGoogle Scholar